Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Vivodyne, which uses AI and robots to grow human tissues in the lab for drug discovery and development, raised a $40M Series A, taking its total funding to $78M (@katmdavis / Axios) https://t.co/9nFzzFfKEp https://t.co/U87bdWWGpZ https://t.co/ZOzeer1FAj
Vivodyne lands $40m to replace animal testing in drug development #longevity #biotech #investment #drugdevelopment https://t.co/CjIcDkXtuj https://t.co/B4GsG0aGiN
Just in: Tevogen $TVGN unveils https://t.co/zCJZucJgax initiative with Microsoft $MSFT and Databricks, aiming to enhance its ExacTcell tech with AI. The move includes expanding HQ for the AI team. #AI #Biotech
Vivodyne, a biotech startup focused on replacing animal testing in drug development by using AI and robotic technology to grow human tissues in the lab, has raised $40 million in a Series A funding round. This latest investment brings the company’s total funding to $78 million. The funding comes amid a broader shift as the FDA and NIH move away from animal testing. Separately, Tevogen has announced a collaboration with Microsoft and Databricks to enhance its ExacTcell technology using artificial intelligence, including plans to expand its AI team headquarters.
